Abstract
OBJECTIVE: To assess cycle outcomes when antimüllerian hormone (AMH) is ultralow (≤0.16 ng/mL) and to determine which parameters contribute to the probability of cycle cancellation and/or outcome.
DESIGN: Retrospective analysis.
SETTING: Not applicable.
PATIENT(S): 5,087 (7.3%) fresh and 243 (1.5%) thawed cycles with ultralow AMH values.
INTERVENTION(S): Linear and logistic regression, comparison with age-matched cycles with normal AMH concentrations.
MAIN OUTCOME MEASURE(S): Cancellation rate; number of retrieved oocytes, embryos, transferred embryos, and cryopreserved embryos; clinical pregnancy, live-birth, and multiple birth rates.
RESULT(S): The total cancellation rate per cycle start for fresh cycles was 54%. Of these, 38.6% of the cycles were canceled before retrieval, and 3.3% of cycles obtained no oocytes at time of retrieval. Of all retrieval attempts, 50.7% had three oocytes or fewer retrieved, and 25.1% had no embryo transfer. The live-birth rates were 9.5% per cycle start. Cycles with ultralow AMH levels compared with age-matched normal AMH cycles demonstrated more than a fivefold greater pre-retrieval cancellation rate, a twofold less live-birth rate per cycle and a 4.5-fold less embryo cryopreservation rate.
CONCLUSION(S): Refusing treatment solely on the basis of ultralow AMH levels is not advisable, but patients should be counseled appropriately about the prognostic factors for cancellation and outcomes.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 385-393 |
| Number of pages | 9 |
| Journal | Fertility and Sterility |
| Volume | 105 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 1 2016 |
Fingerprint
Keywords
- AMH
- ART outcomes
- low AMH
- multiple births
- prognostic factors
- ultralow AMH
ASJC Scopus subject areas
- Medicine(all)
Cite this
Prognostic indicators of assisted reproduction technology outcomes of cycles with ultralow serum antimüllerian hormone : a multivariate analysis of over 5,000 autologous cycles from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database for 2012-2013. / Seifer, David; Tal, Oded; Wantman, Ethan; Edul, Preeti; Baker, Valerie L.
In: Fertility and Sterility, Vol. 105, No. 2, 01.02.2016, p. 385-393.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Prognostic indicators of assisted reproduction technology outcomes of cycles with ultralow serum antimüllerian hormone
T2 - a multivariate analysis of over 5,000 autologous cycles from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database for 2012-2013
AU - Seifer, David
AU - Tal, Oded
AU - Wantman, Ethan
AU - Edul, Preeti
AU - Baker, Valerie L.
PY - 2016/2/1
Y1 - 2016/2/1
N2 - OBJECTIVE: To assess cycle outcomes when antimüllerian hormone (AMH) is ultralow (≤0.16 ng/mL) and to determine which parameters contribute to the probability of cycle cancellation and/or outcome.DESIGN: Retrospective analysis.SETTING: Not applicable.PATIENT(S): 5,087 (7.3%) fresh and 243 (1.5%) thawed cycles with ultralow AMH values.INTERVENTION(S): Linear and logistic regression, comparison with age-matched cycles with normal AMH concentrations.MAIN OUTCOME MEASURE(S): Cancellation rate; number of retrieved oocytes, embryos, transferred embryos, and cryopreserved embryos; clinical pregnancy, live-birth, and multiple birth rates.RESULT(S): The total cancellation rate per cycle start for fresh cycles was 54%. Of these, 38.6% of the cycles were canceled before retrieval, and 3.3% of cycles obtained no oocytes at time of retrieval. Of all retrieval attempts, 50.7% had three oocytes or fewer retrieved, and 25.1% had no embryo transfer. The live-birth rates were 9.5% per cycle start. Cycles with ultralow AMH levels compared with age-matched normal AMH cycles demonstrated more than a fivefold greater pre-retrieval cancellation rate, a twofold less live-birth rate per cycle and a 4.5-fold less embryo cryopreservation rate.CONCLUSION(S): Refusing treatment solely on the basis of ultralow AMH levels is not advisable, but patients should be counseled appropriately about the prognostic factors for cancellation and outcomes.
AB - OBJECTIVE: To assess cycle outcomes when antimüllerian hormone (AMH) is ultralow (≤0.16 ng/mL) and to determine which parameters contribute to the probability of cycle cancellation and/or outcome.DESIGN: Retrospective analysis.SETTING: Not applicable.PATIENT(S): 5,087 (7.3%) fresh and 243 (1.5%) thawed cycles with ultralow AMH values.INTERVENTION(S): Linear and logistic regression, comparison with age-matched cycles with normal AMH concentrations.MAIN OUTCOME MEASURE(S): Cancellation rate; number of retrieved oocytes, embryos, transferred embryos, and cryopreserved embryos; clinical pregnancy, live-birth, and multiple birth rates.RESULT(S): The total cancellation rate per cycle start for fresh cycles was 54%. Of these, 38.6% of the cycles were canceled before retrieval, and 3.3% of cycles obtained no oocytes at time of retrieval. Of all retrieval attempts, 50.7% had three oocytes or fewer retrieved, and 25.1% had no embryo transfer. The live-birth rates were 9.5% per cycle start. Cycles with ultralow AMH levels compared with age-matched normal AMH cycles demonstrated more than a fivefold greater pre-retrieval cancellation rate, a twofold less live-birth rate per cycle and a 4.5-fold less embryo cryopreservation rate.CONCLUSION(S): Refusing treatment solely on the basis of ultralow AMH levels is not advisable, but patients should be counseled appropriately about the prognostic factors for cancellation and outcomes.
KW - AMH
KW - ART outcomes
KW - low AMH
KW - multiple births
KW - prognostic factors
KW - ultralow AMH
UR - http://www.scopus.com/inward/record.url?scp=84976572946&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84976572946&partnerID=8YFLogxK
U2 - 10.1016/j.fertnstert.2015.10.004
DO - 10.1016/j.fertnstert.2015.10.004
M3 - Article
C2 - 26515380
AN - SCOPUS:84949033700
VL - 105
SP - 385
EP - 393
JO - Fertility and Sterility
JF - Fertility and Sterility
SN - 0015-0282
IS - 2
ER -